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Supplementary Figure 2 Durability of 3'UTR-Δ10-LAV-induced neutralizing antibody activities. 13
Ten-week-old A129 mice were immunized with 10 3 FFU 3′UTR-Δ10-LAV (n = 4) or WT ZIKV 14 PRVABC59 (n = 5). The vaccinated mice were bled biweekly from weeks 4 to 30 and finally at 15
week 55 at E0.5. (a) Experimental scheme. Ten-to twelve-week-old pregnant mice were subcutaneously 38 infected with 10 5 FFU WT ZIKV and 3′UTR-Δ10-LAV (Δ10) at E0.5. Placenta and fetus/fetal heads 39
were harvested at E10.5 and E14.5, then samples were analyzed for viral by qPCR. (b) Viral RNA 40 load in placenta at E10.5 and E14.5. (c) Viral RNA load in fetus/fetal heads at E10.5 and E14.5. 41
Since the fetus was just developed at E10.5, the whole fetus was harvested for analysis. While infected with 10 5 FFU WT ZIKV and 3′UTR-Δ10-LAV (Δ10) at E10.5. Maternal and fetal tissues 48
were harvested at E18.5 and analyzed for viral loads and neutralizing antibody titers (NT50). Pups 49
were delivered at E21 and measured for neutralizing antibody titers. (b) The percentage of fetuses 50 that were resorbed during pregnancy (n = 22 for placebo; n = 15 for WT ZIKV; n = 22 for Δ10 51 vaccine; chi-square test [**p<0.01]). The numbers of normal fetuses and total fetuses are 52
presented below each group. (c) Fetal body weights at E18.5 for placebo, WT ZIKV, and Δ10 53 groups. Asterisks indicate significant differences (one-way ANOVA). *significant p<0.5, non-54 significant (n.s.) p>0.5). Viral loads quantified by plaque assay at E18.5 are presented for 55 maternal spleen (d), brain (e), placenta (f), and fetal head (g). Viral RNA quantified by quantitative were mated and immunized with 10 3 FFU 3′UTR-Δ10-LAV or PBS placebo at E0. week-old female mice were subcutaneously immunized with 10 3 FFU of 3′UTR-Δ10-LAV (Δ10) or 107 PBS on day 21 before pregnancy. The pregnant dams gave birth to pups at full term. The female 108 pups were mated with male mice at six-to seven-week-old. At E10.5, these pregnant mice were 109 bled for neutralizing antibody measurement and subcutaneously challenged with 10 6 FFU ZIKV 110
PRVABC59. The challenged pregnant mice were measured for viremia at E12.5. The maternal 111
and fetal organs were harvested for viral load analysis at E18.5. (b) Correlation analysis between 112 NT50 titers at E10.5 and viremia at E12.5. (c) Comparison of NT50 titers and viremia between the 113 protected and infected mice from (b). Correlation analyses between organ viral loads (detected 114 at E18.5) and NT50 titers (measured at E10.5) are presented for maternal brain (d, e) , spleen (f, 115 g), and placenta (h, i). The dotted lines indicate the minimal NT50 titers required for protection 116 against viremia and organ infections. Source data are provided as a Source Data file. 117 118 119
